VALBIOTIS announces a global strategic partnership with NESTLÉ HEALTH SCIENCE for the development and commercialization of TOTUM-63, a plant-derived active substance for prediabetics.

VALBIOTIS, a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the signature of a global long-term strategic partnership with Nestlé Health Science for the development and commercialization of TOTUM-63, an innovative
and patented combination of 5 plant extracts specifically designed to reduce the risk of developing Type 2 Diabetes on prediabetics.
Nestlé Health Science’s global reach and metabolic diseases focus expected to support TOTUM-63 development and global commercialization.
Strategic partnership secures funding for the latest clinical development phase until the obtention of health claims from American and European Authorities.
The deal is structured around an upfront payment of CHF 5 million, development & sales milestone payments up to a maximum of CHF 66 million and tiered royalties on net sales.
Agreement also includes TOTUM-63 supply to Nestlé Health Science representing an additional source of revenue.
As part of the agreement, a joint steering committee comprised of representatives of both companies will oversee clinical development, regulatory matters, supply, and commercialization.

VALBIOTIS
Biopôle Clermont-Limagne
Phone. : +33 546 284 567
Contact : Marc Delaunay | marc.delaunay@valbiotis.com